Sensei Biotherapeutics, Inc. 宣布将公司名称变更为Faeth Therapeutics。这一更名标志着公司战略重心聚焦于推进其核心候选药物Piktor的研发。Piktor是一种口服疗法，旨在靶向癌症中最常发生异常改变的信号通路之一。公司此举旨在更好地反映其专注于开发变革性癌症治疗药物的新方向。
Sensei Biotherapeutics, Inc. 宣布将公司名称变更为Faeth Therapeutics。这一更名标志着公司战略重心聚焦于推进其核心候选药物Piktor的研发。Piktor是一种口服疗法，旨在靶向癌症中最常发生异常改变的信号通路之一。公司此举旨在更好地反映其专注于开发变革性癌症治疗药物的新方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.